149 related articles for article (PubMed ID: 24219551)
1. Treatment approaches to asymptomatic follicular lymphoma.
Sarkozy C; Salles G
Expert Rev Hematol; 2013 Dec; 6(6):747-58. PubMed ID: 24219551
[TBL] [Abstract][Full Text] [Related]
2. Follicular lymphoma: emerging therapeutic strategies.
Kenkre VP; Kahl BS
Expert Rev Hematol; 2010 Aug; 3(4):485-95. PubMed ID: 21083037
[TBL] [Abstract][Full Text] [Related]
3. Current and future management of follicular lymphoma.
Salles G; Ghesquières H
Int J Hematol; 2012 Nov; 96(5):544-51. PubMed ID: 23108535
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of follicular lymphoma.
Cheah CY; Lingaratnam S; Seymour JF
Future Oncol; 2013 Sep; 9(9):1283-98. PubMed ID: 23980675
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?
Kahl B
Hematology Am Soc Hematol Educ Program; 2012; 2012():433-8. PubMed ID: 23233615
[TBL] [Abstract][Full Text] [Related]
6. What is the role of maintenance rituximab in follicular NHL?
Maloney DG
Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
[TBL] [Abstract][Full Text] [Related]
7. Rituximab by subcutaneous route.
Solal-Celigny P
Expert Rev Hematol; 2015 Apr; 8(2):147-53. PubMed ID: 25749209
[TBL] [Abstract][Full Text] [Related]
8. Rituximab maintenance therapy in indolent NHL: a clinical review.
Buske C; Hiddemann W
Leuk Res; 2006 Mar; 30 Suppl 1():S11-5. PubMed ID: 16750673
[TBL] [Abstract][Full Text] [Related]
9. Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?
Lowry L; Ardeshna KM
Cancer J; 2012; 18(5):390-5. PubMed ID: 23006942
[TBL] [Abstract][Full Text] [Related]
10. Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data.
Andemariam B; Leonard JP
Clin Lymphoma Myeloma; 2006 Oct; 7 Suppl 1():S20-3. PubMed ID: 17101069
[TBL] [Abstract][Full Text] [Related]
11. Rituximab maintenance therapy for follicular lymphoma.
Haines I
Lancet; 2011 Apr; 377(9772):1151; author reply 1151-2. PubMed ID: 21459205
[No Abstract] [Full Text] [Related]
12. Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?
Forstpointner R; Dreyling M
Curr Hematol Malig Rep; 2011 Dec; 6(4):207-15. PubMed ID: 21909660
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy in follicular lymphoma.
Michallet AS; Coiffier B; Salles G
Curr Opin Oncol; 2011 Sep; 23(5):449-54. PubMed ID: 21734580
[TBL] [Abstract][Full Text] [Related]
14. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
Grillo-López AJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):323-9. PubMed ID: 12113055
[TBL] [Abstract][Full Text] [Related]
15. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
16. Considerations with newer regimens for indolent non-Hodgkin lymphoma.
Rummel M
Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S128-36. PubMed ID: 18952543
[TBL] [Abstract][Full Text] [Related]
17. Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.
Seiler T; Hiddemann W; Dreyling M
Immunotherapy; 2009 Nov; 1(6):1015-24. PubMed ID: 20635916
[TBL] [Abstract][Full Text] [Related]
18. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
[TBL] [Abstract][Full Text] [Related]
19. Rituximab maintenance versus retreatment in follicular lymphoma.
Palla AR; Hamadani M
Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
[TBL] [Abstract][Full Text] [Related]
20. Primary conjunctival follicular lymphoma treated with the anti-CD20 antibody rituximab and low-dose involved-field radiotherapy.
Takahira M; Okumura H; Minato H; Urushisaki N; Sakurai M; Sugiyama K
Jpn J Ophthalmol; 2007; 51(2):149-51. PubMed ID: 17401629
[No Abstract] [Full Text] [Related]
[Next] [New Search]